glp-1 + b12 longevity microdose Microdosing Low-Dose and Microdose GLP-1 for

Any results referenced from company materials represent self-reported customer data, not clinical trial results, and are not independently verified

Novo Nordisk may have first-mover advantage in the oral space, with oral Wegovy (obesity) and Rybelsus (T2D, launched 2019), but orforglipron is expected to outperform these on-market semaglutide options for a number of reasons: superior HbA1c reduction and weight loss

Be sure to tell your prescriber about any side effects you experience, especially if theyre severe or persistent

Medically reviewed by Charles Kamen, MD, board-certified neurologist Real medical weight loss is about more than the scale